Cardiff Oncology, Inc. today announced that company management will participate in fireside chats and 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference.
| SAN DIEGO, Nov. 21, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in fireside chats and 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference and the JMP Securities Hematology and Oncology Summit taking place on November 29 – December 1, 2022, and December 6 – 7, 2022, respectively.
Details of the fireside chats can be found below. 34th Annual Piper Sandler Healthcare Conference
The JMP Securities Hematology and Oncology Summit
Replays of the fireside chats will be available by visiting the “Events” section of the Cardiff Oncology website and will be archived for 90 days. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com. Cardiff Oncology Contact: Investor Contact:
SOURCE Cardiff Oncology, Inc. | ||||||||||||||||||
Company Codes: NASDAQ-NMS:CRDF |
View original content to download multimedia:
